Trials / No Longer Available
No Longer AvailableNCT02759042
An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study
An Expanded Compassionate Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PRO140_CD02 Study
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- CytoDyn, Inc. · Industry
- Sex
- Male
- Age
- 55 Years – 56 Years
- Healthy volunteers
- —
Summary
The primary objective is to provide continued access to PRO 140 to a subject who has completed participation in PRO140\_CD02.
Detailed description
This is an open label, single center study designed to provide continued access to PRO 140 to a subject who have completed participation in PRO140\_CD02 and continue to receive clinical benefit. The subject will receive weekly PRO 140 SC injection along with oral ART regimen during the Treatment Phase. The study treatment (PRO 140 SC injections) will be administered by a qualified medical professional or self-administered by the subject.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRO 140 | PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5. |
Timeline
- First posted
- 2016-05-03
- Last updated
- 2018-03-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02759042. Inclusion in this directory is not an endorsement.